MedTrace Logo

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

NCT06081595 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-10-13

No results posted yet for this study

Summary

This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .

Conditions

  • Relapsed Ovarian Cancer

Interventions

DRUG

Fluzoparib

Fluzoparib 100mg bid

DRUG

Apatinib

Apatinib 375mg qd

Sponsors & Collaborators

  • Jin Li

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2024-12-30
Completion
2026-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06081595 on ClinicalTrials.gov